trending Market Intelligence /marketintelligence/en/news-insights/trending/ungBwwedT1vA-p3e85ihhQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Astellas, Seattle Genetics' urothelial cancer drug wins US FDA approval

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Astellas, Seattle Genetics' urothelial cancer drug wins US FDA approval

The U.S. Food and Drug Administration approved Bothell, Wash.-based Seattle Genetics Inc.'s and Tokyo-based Astellas Pharma Inc.'s Padcev to treat certain urothelial cancer patients.

Padcev, or enfortumab vedotin-ejfv, is indicated to treat adult patients with locally advanced or spreading urothelial cancer who have not responded to a PD-1/L1 inhibitor — a cancer therapy that targets the immune system — and platinum-containing chemotherapy.

Urothelial cancer, accounting for more than 90% of bladder cancer cases, begins in the urothelial cells that line the urethra, bladder, ureters, renal pelvis and other nearby organs.

The regulator granted accelerated approval to Padcev based on data from a phase-2 single-arm study which showed tumor shrinkage in 44% of 125 patients, while 12% of patients had no signs of cancer after treatment.

Padcev received approval about three months before the expected decision date of March 15, 2020.

The FDA's accelerated approval is a conditional approval for drugs used to treat serious diseases with an unmet need. A further clinical trial is required by the regulator to confirm the drug's benefit to patients.

Padcev, which previously received a breakthrough therapy designation and a priority review designation from the FDA, targets a protein called Nectin-4 that is found in 97% of urothelial cancers. The drug is an antibody-drug conjugate, a type of drug that specifically targets cancer cells.